全文获取类型
收费全文 | 56319篇 |
免费 | 5775篇 |
国内免费 | 131篇 |
专业分类
耳鼻咽喉 | 388篇 |
儿科学 | 1656篇 |
妇产科学 | 1145篇 |
基础医学 | 8176篇 |
口腔科学 | 1327篇 |
临床医学 | 6733篇 |
内科学 | 11698篇 |
皮肤病学 | 882篇 |
神经病学 | 4634篇 |
特种医学 | 2105篇 |
外国民族医学 | 1篇 |
外科学 | 7522篇 |
综合类 | 1188篇 |
现状与发展 | 1篇 |
一般理论 | 35篇 |
预防医学 | 5954篇 |
眼科学 | 921篇 |
药学 | 4480篇 |
中国医学 | 98篇 |
肿瘤学 | 3281篇 |
出版年
2022年 | 375篇 |
2021年 | 820篇 |
2020年 | 503篇 |
2019年 | 879篇 |
2018年 | 1007篇 |
2017年 | 703篇 |
2016年 | 813篇 |
2015年 | 941篇 |
2014年 | 1311篇 |
2013年 | 1867篇 |
2012年 | 2822篇 |
2011年 | 2888篇 |
2010年 | 1605篇 |
2009年 | 1586篇 |
2008年 | 2700篇 |
2007年 | 2856篇 |
2006年 | 2810篇 |
2005年 | 2788篇 |
2004年 | 2599篇 |
2003年 | 2461篇 |
2002年 | 2384篇 |
2001年 | 1622篇 |
2000年 | 1506篇 |
1999年 | 1568篇 |
1998年 | 748篇 |
1997年 | 579篇 |
1996年 | 553篇 |
1995年 | 570篇 |
1994年 | 494篇 |
1993年 | 542篇 |
1992年 | 1246篇 |
1991年 | 1164篇 |
1990年 | 1107篇 |
1989年 | 1066篇 |
1988年 | 994篇 |
1987年 | 997篇 |
1986年 | 1002篇 |
1985年 | 903篇 |
1984年 | 786篇 |
1983年 | 652篇 |
1982年 | 439篇 |
1981年 | 370篇 |
1980年 | 366篇 |
1979年 | 595篇 |
1978年 | 491篇 |
1977年 | 377篇 |
1976年 | 385篇 |
1974年 | 434篇 |
1973年 | 401篇 |
1972年 | 388篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Chouraqui Jean-Pierre Tavoularis Gabriel Simeoni Umberto Ferry Constance Turck Dominique 《European journal of nutrition》2020,59(1):67-80
European Journal of Nutrition - The French Nutri-Bébé 2013 study aimed to assess the nutritional intake of infants and young children in comparison with the recommendations of the 2013... 相似文献
2.
3.
4.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献
5.
6.
Catherine L. Omosule Dominique Joseph Brooke Weiler Victoria L. Gremminger Spencer Silvey Youngjae Jeong Ashique Rafique Pamela Krueger Sandra Kleiner Charlotte L. Phillips 《Journal of bone and mineral research》2022,37(5):938-953
Osteogenesis imperfecta (OI) is a collagen-related bone disorder characterized by fragile osteopenic bone and muscle weakness. We have previously shown that the soluble activin receptor type IIB decoy (sActRIIB) molecule increases muscle mass and improves bone strength in the mild to moderate G610C mouse model of OI. The sActRIIB molecule binds multiple transforming growth factor-β (TGF-β) ligands, including myostatin and activin A. Here, we investigate the musculoskeletal effects of inhibiting activin A alone, myostatin alone, or both myostatin and activin A in wild-type (Wt) and heterozygous G610C (+/G610C) mice using specific monoclonal antibodies. Male and female Wt and +/G610C mice were treated twice weekly with intraperitoneal injections of monoclonal control antibody (Ctrl-Ab, Regn1945), anti-activin A antibody (ActA-Ab, Regn2476), anti-myostatin antibody (Mstn-Ab, Regn647), or both ActA-Ab and Mstn-Ab (Combo, Regn2476, and Regn647) from 5 to 16 weeks of age. Prior to euthanasia, whole body composition, metabolism and muscle force generation assessments were performed. Post euthanasia, hindlimb muscles were evaluated for mass, and femurs were evaluated for changes in microarchitecture and biomechanical strength using micro–computed tomography (μCT) and three-point bend analyses. ActA-Ab treatment minimally impacted the +/G610C musculoskeleton, and was detrimental to bone strength in male +/G610C mice. Mstn-Ab treatment, as previously reported, resulted in substantial increases in hindlimb muscle weights and overall body weights in Wt and male +/G610C mice, but had minimal skeletal impact in +/G610C mice. Conversely, the Combo treatment outperformed ActA-Ab alone or Mstn-Ab alone, consistently increasing hindlimb muscle and body weights regardless of sex or genotype and improving bone microarchitecture and strength in both male and female +/G610C and Wt mice. Combinatorial inhibition of activin A and myostatin more potently increased muscle mass and bone microarchitecture and strength than either antibody alone, recapturing most of the observed benefits of sActRIIB treatment in +/G610C mice. © 2022 American Society for Bone and Mineral Research (ASBMR). 相似文献
7.
8.
9.